Announcement • Jul 23
Lonza Group Ag Provides Earnings Guidance for the Second Half and Full Year 2026 Lonza Group AG provided earnings guidance for the second half and full year 2026. For the second half, as the company did exceptionally strong performance in this business platform in H1 2026 and anticipate higher absolute sales in H2, the company envisage that CER sales growth will moderate in H2 as planned due to a combination of less favorable phasing and portfolio mix alongside a higher base in H2 2025. Similarly, margins will normalize in the second half of the year as expected.
For the full year, the company full year 2026 sales expected to be broadly flat versus full year 2025 at around CHF 0.6 billion. Reported Earnings • Jul 22
First half 2026 earnings: EPS exceeds analyst expectations First half 2026 results: EPS: CHF8.14 (up from CHF5.65 in 1H 2025). Revenue: CHF3.37b (up 11% from 1H 2025). Net income: CHF568.0m (up 43% from 1H 2025). Profit margin: 17% (up from 13% in 1H 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.5%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year. Buy Or Sell Opportunity • Jul 06
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to CHF574. The fair value is estimated to be CHF474, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 16%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 18% per annum over the same time period. Live News • Jul 02
Lonza Group Partners With Nona Biosciences on Antibody Platform for CNS Drug Development Lonza Group and Nona Biosciences have entered a collaboration to develop single-domain antibody-based blood-brain barrier crossing technology for central nervous system diseases. The agreement combines Nona’s Harbour Mice platform with Lonza’s GS Gene Expression System and GlycoConnect bioconjugation technology, with an eye to future licensing and commercialization.
The partnership gives Lonza another channel to apply its biologics development and manufacturing capabilities in a specialised CNS setting. This could broaden its role in complex antibody and conjugate projects if the technology translates into viable drug candidates.
Lonza’s shares trade at CHF562.60, with the stock up 13.4% over the past 30 days, which frames this announcement against a backdrop of recent share price strength.
This collaboration adds a higher-value R&D layer to Lonza’s service offering, but execution risk around new CNS platforms and the timing of any licensing income remain key uncertainties. Announcement • Jun 25
Lonza Group Reportedly Explores Sale of Capsules and Health Ingredients Division Lonza Group Ltd. (SWX:LONN) is reportedly exploring the sale of its capsules and health ingredients division, valued at approximately €2,500 million, as part of a strategic portfolio review. The planned divestment is intended to refocus the Swiss contract development and manufacturing organization (CDMO) on its core biologics and drug substance services, according to reports from Russian news agency AK&M. The report, dated June 19, 2026, indicates that Lonza Group is collaborating with Bank of America and Centerview Partners to assess the potential sale of this division. Notable private equity firms, including Lone Star (Lone Star Americas Acquisitions, Inc.), Altaris (Altaris, LLC), and One Rock Capital Partners (One Rock Capital Partners, LLC), are among the potential bidders vying for the business, which would represent a significant carve-out from Lonza's existing portfolio. This move aligns with a broader trend observed among European life-science suppliers, who are increasingly concentrating on higher-margin contract development and manufacturing services. As companies like Catalent and Sartorius have shown, there is a growing focus on capital allocation discipline and portfolio streamlining. Lonza Group's reported divestment is consistent with this narrative, sharpening its exposure to biologics and complex therapies, while divesting from more commoditized activities. Live News • Jun 16
Lonza Group Stock Eyes Growth With Exclusive ADC Licensing Deal in Oncology Manufacturing Lonza Group granted Antharis Therapeutics an exclusive license to develop next-generation dual payload antibody-drug conjugates (ADCs) aimed at gastrointestinal cancers.
The agreement is structured to use Lonza’s biologics development expertise and contract development and manufacturing organization (CDMO) capabilities for oncology-focused therapies.
The partnership underscores Lonza’s role in supplying complex synthesis and manufacturing services to emerging biotech companies in the ADC field.
This licensing deal reinforces Lonza Group’s positioning in high-complexity biologics and ADC manufacturing, an area where technical barriers can create meaningful differentiation among CDMO providers.
Investors may want to watch how effectively Lonza converts such partnerships into long-term development and manufacturing contracts, as execution risk and clinical outcomes at Antharis could influence the ultimate value of this collaboration. Announcement • Jun 09
LONZA GROUP LTD Announces Management Changes LONZA GROUP LTD announced the appointment of Hans Trees as Global Head of Communications, Senior Vice President and member of the Extended Executive Committee. Hans will join Lonza on 1 September 2026 and succeed David Carter, who has led Lonza's Communications function since 2019. Hans is a seasoned communications executive with broad experience across communications, strategy and business leadership in global organizations. Most recently, he served as Roche's Global Head of External Engagement. Over an 11-year career at Roche, he held a number of leadership roles in both the Pharmaceuticals Division and Group functions. Prior to joining Roche, he worked in management consulting at AON and investment banking at Rothschild. Hans holds degrees from the University of Cambridge, the London School of Economics and University of Durham. Board Change • Jun 01
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Director Steve Fry was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 05
Upcoming dividend of CHF5.00 per share Eligible shareholders must have bought the stock before 12 May 2026. Payment date: 15 May 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Swiss dividend payers (3.7%). In line with average of industry peers (1.1%). Announcement • Apr 23
Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug Products Simulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives. Announcement • Apr 15
Lonza Group AG Proposes Final Cash Dividend, Payable on May 15, 2026 Lonza Group AG proposed final cash dividend of CHF 2.50 per share (Gross dividend per equity), Net dividend per equity of CHF 1.625 per share. Date of GM: May 8, 2026, Ex date: May 12, 2026, Payment date: May 15, 2026, Record date: May 13, 2026. Declared Dividend • Apr 04
Dividend increased to CHF5.00 Dividend of CHF5.00 is 25% higher than last year. Ex-date: 12th May 2026 Payment date: 15th May 2026 Dividend yield will be 1.0%, which is about the same as the industry average. Reported Earnings • Apr 02
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 7.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Apr 02
Lonza Group AG, Annual General Meeting, May 08, 2026 Lonza Group AG, Annual General Meeting, May 08, 2026, at 10:00 W. Europe Standard Time. Major Estimate Revision • Feb 06
Consensus revenue estimates fall by 10% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CHF8.34b to CHF7.47b. EPS estimate fell from CHF18.13 to CHF16.71 per share. Net income forecast to grow 29% next year vs 22% growth forecast for Life Sciences industry in Switzerland. Consensus price target broadly unchanged at CHF673. Share price was steady at CHF517 over the past week. Reported Earnings • Jan 30
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CHF12.98 (up from CHF8.94 in FY 2024). Revenue: CHF6.53b (flat on FY 2024). Net income: CHF909.0m (up 43% from FY 2024). Profit margin: 14% (up from 9.7% in FY 2024). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 5.5%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Oct 24
Lonza Group Ag Affirms Earnings Guidance for 2025 Lonza Group AG affirmed earnings guidance for 2025. For the period, company expects CER sales growth of 20-21%. Announcement • Sep 13
Lonza Group AG Announces Executive Changes, Effective October 1, 2025 Lonza Group AG announced the appointment of Jason Berndt as Head of Group Operations, Executive Vice President, and member of the Executive Committee (EC), effective October 1, 2025. Jason brings over two decades of experience in global operations, having held leadership roles in operational excellence, manufacturing, supply chain management, technical services, and network transformations across leading pharmaceutical and consumer goods companies. He most recently served as Head of Global Technical Services and Senior Vice President at Bristol-Myers Squibb. Prior to this, he spent over eight years in leadership roles at Teva Pharmaceuticals, six years in manufacturing operations at Procter & Gamble, and two years as a consultant at McKinsey and Company. Jason began his career in the US Army, serving five years as a military officer. He holds a Bachelor of Science degree from the United States Military Academy at West Point and an MBA from the University of Michigan. Maria Soler Nunez, currently Head of Group Operations, has been appointed as Chief Quality Officer and Executive Vice President, remaining a member of the EC, effective October 1, 2025. Maria joined Lonza in 2022 and has successfully led Lonza’s engineering, procurement, supply chain management, operational excellence, and program management Group Functions. In her new role, she will be responsible for upholding and reinforcing the highest quality standards across Lonza’s global development and manufacturing network, as well as overseeing regulatory affairs and regulatory compliance. Maria has 28 years of experience in manufacturing and quality roles in the pharmaceutical industry, having worked in multiple countries including Spain, Switzerland, and the US. Before joining Lonza, she served as Chief Quality Officer at Novartis and worked with Eli Lilly and Company for 12 years. Commencing 1 October 2025 and continuing until his retirement in 2026, Oliver Schläfli, currently serving as Global Head of Quality, will transfer his responsibilities to Maria and provide counsel on different projects across the organization. Reported Earnings • Jul 24
First half 2025 earnings: EPS in line with analyst expectations despite revenue beat First half 2025 results: EPS: CHF6.08 (up from CHF4.61 in 1H 2024). Revenue: CHF3.58b (up 17% from 1H 2024). Net income: CHF426.0m (up 30% from 1H 2024). Profit margin: 12% (up from 11% in 1H 2024). Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Upcoming Dividend • May 06
Upcoming dividend of CHF4.00 per share Eligible shareholders must have bought the stock before 13 May 2025. Payment date: 15 May 2025. Payout ratio is a comfortable 45% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Swiss dividend payers (4.0%). In line with average of industry peers (0.8%). Declared Dividend • Apr 06
Dividend of CHF4.00 announced Shareholders will receive a dividend of CHF4.00. Ex-date: 13th May 2025 Payment date: 15th May 2025 Dividend yield will be 0.8%, which is lower than the industry average of 0.9%. Announcement • Feb 20
Lonza Reportedly Is Said to Tap Bofa, Centerview for Sale of Capsules Unit Lonza Group AG (SWX:LONN) has selected Bank of America Corp. and Centerview Partners to arrange the sale of its capsules and health ingredients business (Capsugel, Inc.), according to people familiar with the matter, as part of the firm’s efforts to streamline its corporate structure. The capsules unit could be worth at least €2.5 billion ($2.6 billion) in a deal, said one of the people, who asked not to be identified as the information is private. Deliberations are ongoing and details of a transaction could still change, the people said. New Risk • Jan 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 31% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Jan 30
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: CHF8.93. Revenue: CHF6.57b (down 2.1% from FY 2023). Net income: CHF636.0m (down 2.8% from FY 2023). Profit margin: 9.7% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 23%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Announcement • Oct 30
Lonza Group AG to Report First Half, 2025 Results on Jul 23, 2025 Lonza Group AG announced that they will report first half, 2025 results on Jul 23, 2025 Announcement • Oct 24
Lonza Group AG Provides Earnings Guidance for Full Year 2024 Lonza Group AG provided earnings guidance for full year 2024. The company reported a third quarter performance in line to deliver on its Full-year Outlook, with sales accelerating in fourth quarter based on the timing of batch releases. In this context, the company confirms its Full-year Outlook 2024 at flat year-on year sales in CER and a CORE EBITDA margin of high 20s. Operations at the new highly potent API facility in Visp are expected to commence in fourth quarter of 2024, with a significant sales contribution expected in 2025. Furthermore, construction remains on track at the large-scale commercial aseptic drug product facility in Stein (CH). Buy Or Sell Opportunity • Oct 12
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 1.4% to CHF525. The fair value is estimated to be CHF437, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 2.9%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 24% per annum over the same time period. Announcement • Oct 02
Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Lonza Group AG (SWX:LONN) entered into an agreement to acquire Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG) for $1.2 billion on March 20, 2024. Under the agreement, approximately 750 Genentech employees at the Vacaville (US) facility will be offered employment by Lonza. The transaction is subject to customary closing conditions. Upon closing, the Vacaville (US) site will be integrated into Lonza’s Biologics division, joining a network of existing mammalian manufacturing sites in Visp (CH), Slough (UK), Singapore (SG), Portsmouth (US) and Porriño (ES). The transaction is expected to close in H2 2024. As the transaction is expected to be accretive to sales growth, Lonza has updated its Mid-Term Guidance 2024 – 2028. BofA Securities acted as financial advisors to Lonza.
Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG) on October 1, 2024. Reported Earnings • Jul 28
First half 2024 earnings: EPS in line with analyst expectations despite revenue beat First half 2024 results: EPS: CHF4.61 (down from CHF5.54 in 1H 2023). Revenue: CHF3.06b (flat on 1H 2023). Net income: CHF329.0m (down 20% from 1H 2023). Profit margin: 11% (down from 13% in 1H 2023). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 28
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to CHF581. The fair value is estimated to be CHF484, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 2.9%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. Announcement • Jul 26
Lonza Group AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Lonza Group AG announced that they will report fiscal year 2024 results on Jan 30, 2025 Announcement • May 12
Lonza Group AG Announces Board Changes Lonza Group AG announced that Albert M. Baehny, former Chairman of the Board of Directors, did not stand for re-election at the Annual General Meeting (AGM) of 8 May 2024. Jean-Marc Huët has been elected as new member and Chairman of the Board of Directors at this AGM. Announcement • May 11
Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024 Lonza Group AG at its AGM held on May 8, 2024 approved Final cash dividend of CHF 2.00 per share and Share premium dividend of CHF 2.00 per share. Ex date is May 13, 2024, payment date is May 15, 2024 and record date is May 14, 2024. Reported Earnings • Apr 05
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CHF8.88 (down from CHF16.37 in FY 2022). Revenue: CHF6.72b (up 7.9% from FY 2022). Net income: CHF654.0m (down 46% from FY 2022). Profit margin: 9.7% (down from 20% in FY 2022). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) missed analyst estimates by 31%. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Declared Dividend • Apr 04
Dividend increased to CHF4.00 Dividend of CHF4.00 is 14% higher than last year. Ex-date: 13th May 2024 Payment date: 15th May 2024 Dividend yield will be 0.7%, which is lower than the industry average of 0.9%. Buy Or Sell Opportunity • Apr 03
Now 21% undervalued Over the last 90 days, the stock has risen 52% to CHF533. The fair value is estimated to be CHF672, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 9.5% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Announcement • Apr 02
Lonza Group AG Announces Chief Executive Officer Changes Lonza Group AG announced that Wolfgang Wienand has been appointed Chief Executive Officer (CEO), and will join the company during the summer of 2024. Wolfgang is currently CEO of the Swiss contract development and manufacturing organization (CDMO) Siegfried Holding AG, a role he has held since 2019. Prior to this, Wolfgang first served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Before joining Siegfried in 2010, Wolfgang held a series of increasingly senior positions at the German specialty chemicals company Evonik Industries. Wolfgang will succeed Albert M. Baehny, who took on the additional responsibility of CEO on an ad interim basis in October 2023 while the search for a permanent CEO took place. Albert will remain at Lonza for a transition period during the summer, before retiring from the company. Buy Or Sell Opportunity • Feb 20
Now 20% undervalued Over the last 90 days, the stock has risen 29% to CHF454. The fair value is estimated to be CHF569, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 19% per annum over the same time period. Price Target Changed • Feb 02
Price target increased by 7.3% to CHF503 Up from CHF468, the current price target is an average from 20 analysts. New target price is 18% above last closing price of CHF428. Stock is down 23% over the past year. The company is forecast to post earnings per share of CHF12.02 for next year compared to CHF8.88 last year. Reported Earnings • Jan 27
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CHF8.88 (down from CHF16.37 in FY 2022). Revenue: CHF6.72b (up 7.9% from FY 2022). Net income: CHF654.0m (down 46% from FY 2022). Profit margin: 9.7% (down from 20% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) missed analyst estimates by 31%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Jan 12
Lonza Group AG to Report Fiscal Year 2023 Results on Jan 26, 2024 Lonza Group AG announced that they will report fiscal year 2023 results on Jan 26, 2024 Announcement • Jan 07
Lonza Group AG, Annual General Meeting, May 08, 2024 Lonza Group AG, Annual General Meeting, May 08, 2024. Price Target Changed • Dec 12
Price target decreased by 8.9% to CHF463 Down from CHF508, the current price target is an average from 18 analysts. New target price is 43% above last closing price of CHF325. Stock is down 32% over the past year. The company is forecast to post earnings per share of CHF12.70 for next year compared to CHF16.37 last year. Price Target Changed • Oct 27
Price target decreased by 8.4% to CHF539 Down from CHF588, the current price target is an average from 18 analysts. New target price is 71% above last closing price of CHF315. Stock is down 39% over the past year. The company is forecast to post earnings per share of CHF12.66 for next year compared to CHF16.37 last year. Price Target Changed • Oct 20
Price target decreased by 8.5% to CHF569 Down from CHF623, the current price target is an average from 17 analysts. New target price is 66% above last closing price of CHF342. Stock is down 31% over the past year. The company is forecast to post earnings per share of CHF12.58 for next year compared to CHF16.37 last year. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CHF357, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 28x in the Life Sciences industry in Switzerland. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF550 per share. Announcement • Sep 21
Lonza Group AG Provides Sales Guidance for the Year 2023 Lonza Group AG provided sales guidance for the year 2023. The company is reconfirming its Outlook 2023. During the company’s Half-Year Results presentation in July 2023, the Outlook was set at mid-to-high single-digit CER sales growth. Buying Opportunity • Sep 19
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be CHF555, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 15% per annum over the same time period. Announcement • Sep 18
Lonza Group AG Announces CEO Changes Lonza Group AG announced that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September 2023 by mutual agreement. The Board of Directors also announced that Albert M. Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is appointed. Major Estimate Revision • Jul 28
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CHF6.62b to CHF6.46b. EPS estimate also fell from CHF14.73 per share to CHF12.99 per share. Net income forecast to shrink 7.4% next year vs 4.0% decline forecast for Life Sciences industry in Switzerland. Consensus price target down from CHF681 to CHF651. Share price rose 2.1% to CHF501 over the past week. New Risk • Jul 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swiss stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 23
First half 2023 earnings: EPS and revenues miss analyst expectations First half 2023 results: EPS: CHF5.54 (down from CHF6.67 in 1H 2022). Revenue: CHF3.08b (up 3.2% from 1H 2022). Net income: CHF410.0m (down 17% from 1H 2022). Profit margin: 13% (down from 17% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. 
